Skip to main content
. 2020 Jun 11;76(11):1363–1374. doi: 10.1016/j.jacc.2020.06.019

Table 3.

Effect on QTc and Proarrhythmia of Experimental Pharmacological Therapies for COVID-19 (36)

QTc Prolongation TdP Risk
Chloroquine (37, 38, 39, 40) Moderate ↑ Low risk of TdP
Hydroxychloroquine (41) Moderate ↑ Low risk of TdP
Azithromycin (42, 43, 44, 45, 46, 47, 48) Moderate ↑ Very low risk of TdP
Lopinavir/Ritonavir (37) Moderate ↑ Low risk of TdP
Tocilizumab (49) Mild ↑ or ↓ NR
Fingolimod Mild ↑ NR
Remdesivir NR NR
Interferon alfacon-1 NR NR
Ribavirin NR NR
Methylprednisolone NR NR

NR = not reported; TdP = torsade de pointes.